FORMA THERAPEUTICS ACHIEVES SECOND MAJOR OBJECTIVE IN COLLABORATION WITH CELGENE CORPORATION TO ADVANCE INNOVATIVE PROTEIN HOMEOSTASIS DRUGS

WATERTOWN, Mass. – February 24, 2015 – FORMA Therapeutics announced today that it has successfully met a second objective under its strategic collaboration agreement with Celgene Corporation, triggering an undisclosed payment from Celgene. In April 2013, FORMA and Celgene entered into a collaboration to discover, develop and commercialize drug candidates to regulate protein homeostasis targets. This collaboration enables Celgene to evaluate selected targets and lead assets in protein homeostasis pathways during preclinical development.

Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics, said, “We are pleased to have identified novel chemical matter and robust chemical tool compounds which supported interrogation of the potential clinical utility for this target. Celgene’s steadfast commitment to oncology and novel areas of biology is testament to Celgene’s mission of improving the lives of patients worldwide. FORMA’s alliance with Celgene provides a unique opportunity to discover, advance and accelerate a broad pipeline of novel therapies to impact human health.”

About Protein Homeostasis

Protein homeostasis, which is important in oncology, neurodegenerative and other disorders, involves a tightly regulated network of pathways controlling the biogenesis, folding, transport and degradation of proteins. Exploring the maintenance and regulation of such competing, yet integrated, biological pathways using a chemical biology approach should directly contribute to the understanding of diseases associated with excessive protein misfolding, aggregation and degradation.

About FORMA

FORMA Therapeutics’ scientists are passionate about discovering and developing medicines that will make a difference in oncology and other genetically driven therapeutic areas. The company’s drug discovery engine drives screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions. Deep biological insight across targets is combined with the company’s chemistry expertise and integrated with a world class network of academic investigators, clinical experts and corporate partners to rapidly direct the creation of high quality, innovative drug candidates.

FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with additional chemistry operations in Branford, CT. www.formatherapeutics.com

Join our conversation on Twitter @FORMAInc.

Media Contact

For FORMA Therapeutics
Kari Watson or Charles Liles, +1 781-235-3060
kwatson@macbiocom.com or cliles@macbiocom.com
MacDougall Biomedical Communications